IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
- 20 June 2024
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 42 (7) , 1185-1201.e14
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Institutes of Health
This publication has 77 references indexed in Scilit:
- ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesisCancer Cell, 2024
- SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisionsCancer Cell, 2024
- Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesCancer Cell, 2023
- 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanomaAnnals of Oncology, 2023
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2022
- Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling ComplexesCell, 2018
- A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell NeoplasmCancer Cell, 2016
- Transcriptional Amplification in Tumor Cells with Elevated c-MycCell, 2012
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell LymphomaCancer Cell, 2012
- A SNP microarray and FISH‐based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effectGenes, Chromosomes and Cancer, 2009